Do you have psoriatic arthritis (PsA)? Have you taken guselkumab? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients to provide input to patient organizations on the manufacturer’s submission for guselkumab for the treatment of psoriatic arthritis (PsA).
All new drugs are submitted for review by the joint federal/provincial/territorial Common Drug Review (CDR) which makes recommendations for listing drugs that the federal, provincial and territorial drug plans then consider for public reimbursement. The CDR is a program of the Canadian Agency for Drugs and Technologies in Health (CADTH), an independent, not-for-profit agency, funded by participating governments (all, except Quebec).
CADTH has implemented a process by which patient groups would have input into drug review and decision-making around public drug plan formulary listings. Organizations supporting patients living with psoriatic arthritis develop these patient input submissions whenever a drug of interest to people living with psoriatic arthritis is under consideration. We would like to gather your views and share them with the CDR. Your views will be anonymous.
For this submission, five Canadian organizations are working together, including, the Canadian Psoriasis Network (CPN), the Canadian Association of Psoriasis Patients (CAPP), the Canadian Arthritis Patient Alliance (CAPA), the Arthritis Society (TAS), and CreakyJoints Canada. Your responses to this survey will only be shared among key members of our organizations as we work together to provide feedback to the CDR process. Your responses will be kept confidential and we will not disclose any identifying information.
If you have any questions or comments, please contact your community representative:
Arthritis Society: Luke Fox – email@example.com
CAPA: Laurie Proulx - firstname.lastname@example.org
CAPP: Rachael Manion - email@example.com
CPN: Antonella Scali - firstname.lastname@example.org
CreakyJoints Canada: Adam Kegley - email@example.com
Feel free to email any of us if you’d prefer to give your input by telephone.
The survey should take approximately 15-20 minutes to complete.
Please submit your responses by May 13, 2022.